State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, 410082, People's Republic of China.
Department of Modern Economy and Trade, Hunan Vocational College of Engineering, Changsha, 410151, People's Republic of China.
Top Curr Chem (Cham). 2021 Jan 11;379(1):4. doi: 10.1007/s41061-020-00318-2.
COVID-19 has broken out rapidly in nearly all countries worldwide, and has blossomed into a pandemic. Since the beginning of the spread of COVID-19, many scientists have been cooperating to study a vast array of old drugs and new clinical trial drugs to discover potent drugs with anti-COVID-19 activity, including antiviral drugs, antimalarial drugs, immunosuppressants, Chinese medicines, M inhibitors, JAK inhibitors, etc. The most commonly used drugs are antiviral compounds, antimalarial drugs and JAK inhibitors. In this review, we summarize mainly the antimalarial drugs chloroquine and hydroxychloroquine, the antiviral drugs Favipiravir and Remdesivir, and JAK inhibitor Ruxolitinib, discussing their biological activities, clinical trials and synthesis progress.
新型冠状病毒肺炎（Corona Virus Disease 2019，COVID-19）在全球近所有国家迅速爆发，并蔓延成为一场大流行。自 COVID-19 传播开始以来，许多科学家一直在合作研究大量旧药物和新临床试验药物，以发现具有抗 COVID-19 活性的有效药物，包括抗病毒药物、抗疟药物、免疫抑制剂、中药、M 抑制剂、JAK 抑制剂等。最常用的药物是抗病毒化合物、抗疟药物和 JAK 抑制剂。在本综述中，我们主要总结了抗疟药物氯喹和羟氯喹、抗病毒药物法匹拉韦和瑞德西韦以及 JAK 抑制剂芦可替尼，讨论了它们的生物学活性、临床试验和合成进展。
Zotero 插件
